A novel and selective sodium‐glucose cotransporter‐2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus

Publisher: John Wiley & Sons Inc

E-ISSN: 1463-1326|17|10|984-993

ISSN: 1462-8902

Source: DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol.17, Iss.10, 2015-10, pp. : 984-993

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content